-
公开(公告)号：US20220305082A1
公开(公告)日：2022-09-29
申请号：US17826954
申请日：2022-05-27
申请人： CentricsBio, Inc.
发明人： Jaewon JEON , Haneul KIM , Suin LEE
摘要： A chimeric antigen receptor that specifically binds to a CD300c antigen or a receptor thereof, immune cells expressing the same, and uses thereof are disclosed. The chimeric antigen receptor that specifically binds to a CD300c antigen or a receptor thereof is able to specifically recognize cancer cells expressing the CD300c antigen or the CD300c receptor so that growth, metastasis, development, and the like of cancer can be suppressed in a direct and effective manner. Thus, it is expected that the chimeric antigen receptor can be effectively used as an immunotherapeutic agent for various cancers.
-
公开(公告)号：US20220280663A1
公开(公告)日：2022-09-08
申请号：US17745016
申请日：2022-05-16
申请人： CELLIS AG
发明人： Magdalena KROL , Irene BENNI , Paola BAIOCCO , Tomasz RYGIEL , Alberto BOFFI , Aleksandra SZULC , Zofia PILCH , Katarzyna TONECKA , Katarzyna ULEWICZ , Bartlomiej TACIAK , Lukasz KIRAGA
IPC分类号： A61K51/12 , A61K47/68 , A61K47/64 , A61K47/69 , A61K35/15 , A61K35/17 , A61K45/06 , A61K49/00 , A61K49/18 , A61K51/04 , C12N5/0783 , C12N5/0787 , C12N5/0786
摘要： The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active pharmaceutically active substance and/or label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for prophylaxis, therapy, diagnosis or theragnosis, in particular for prophylactic or therapeutic vaccination, therapy of cancer, particularly metastatic cancer or inflammatory diseases.
-
53.发明申请公开(公告)号：US20220280486A1
公开(公告)日：2022-09-08
申请号：US17632183
申请日：2020-08-14
IPC分类号： A61K31/427 , A61K39/395 , A61K35/15
摘要： The present disclosure relates generally to novel approaches to activate integrin signaling in order to overcome CD47 checkpoint inhibition and to promote macrophage phagocytic signaling pathway. The disclosure also provides methods and compositions for treatment of cancer, including solid tumor and hematologic malignancy, by promoting macrophage-mediated engulfment of cancer cells. Use of integrin activation in combination with adoptive transfer of engineered macrophages to increase engulfment of cancer cells is also provided.
-
公开(公告)号：US20220273856A1
公开(公告)日：2022-09-01
申请号：US17748646
申请日：2022-05-19
申请人： Fenwal, Inc.
摘要： Methods and systems for maintaining patient fluid balance during an extracorporeal cell treatment are disclosed. The method includes minimizing the amount of saline or other fluid that is returned to the donor. Saline used during priming of the fluid circuit may be used to increase the volume of the collected cells to arrive at a treatment-ready product with a suitable hematocrit.
-
公开(公告)号：US11413338B2
公开(公告)日：2022-08-16
申请号：US16511413
申请日：2019-07-15
发明人： Serhat Gumrukcu
摘要： Disclosed herein are methods and compositions for treating cancer by eliciting an immune response by administering dendritic cells expressing heterologous proteins. In some embodiments, a dendritic cell comprises one or more heterologous nucleic acid molecules encoding for CD40L and CXCL13. In some embodiments, the dendritic cell further comprises a heterologous nucleic acid molecule encoding for CD93. In yet additional embodiments, the dendritic cells expressing heterologous proteins are activated.
-
公开(公告)号：US11412730B2
公开(公告)日：2022-08-16
申请号：US15737469
申请日：2016-06-30
IPC分类号： A01N1/02 , A61K47/20 , A61K47/26 , A61K47/42 , A61K35/33 , A61K35/34 , A61K38/38 , A61K35/15 , A61K35/17 , A61K9/00 , A61K47/18 , A61K35/14 , A61K35/28
摘要： Disclosed is a composition including, in a physiologically acceptable medium: a) human albumin; b) at least one saccharide; c) DMSO and L-cysteine or coenzyme Q10; and d) cells for therapeutic purposes, with the exception of specific tumour-infiltrating lymphocytes.
-
公开(公告)号：US20220249664A1
公开(公告)日：2022-08-11
申请号：US17469625
申请日：2021-09-08
申请人： Bioverativ USA Inc.
发明人： Graham Parry , Pavel A. Nikitin , Sandip Panicker
IPC分类号： A61K39/395 , C07K16/40 , C07K16/42 , A61K35/15
摘要： The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring, the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual.
-
公开(公告)号：US20220218744A1
公开(公告)日：2022-07-14
申请号：US17612441
申请日：2019-08-19
申请人： CellAxia Inc.
IPC分类号： A61K35/15 , C12N5/0786 , A61P29/00
摘要： A pharmaceutical composition containing a cell population with enriched M2 macrophage and a pharmaceutically acceptable carrier is provided. The composition is not trapped in the lungs when administered systemically, and accumulates at a disorder/inflammation site. Therefore, the pharmaceutical composition of the present invention is useful as an anti-inflammatory pharmaceutical composition.
-
公开(公告)号：US20220204942A1
公开(公告)日：2022-06-30
申请号：US17695546
申请日：2022-03-15
申请人： Organovo, Inc.
摘要： Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.
-
公开(公告)号：US20220204941A1
公开(公告)日：2022-06-30
申请号：US17695538
申请日：2022-03-15
申请人： Organovo, Inc.
摘要： Disclosed are methods of assessing the ability of a candidate therapeutic agent to reverse, reduce or prevent intestinal injury by a potential toxic agent using a three-dimensional, engineered, bioprinted, biological intestinal tissue model. Also disclosed are methods of assessing the effect of an agent on intestinal function, the method comprising contacting the agent with a three-dimensional, engineered, bioprinted, biological intestinal tissue model.
-
-
-
-
-
-
-
-
-
搜索结果
1148 条记录 (耗时 0.031 秒)
